Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease (ILD): impact of pulmonary arterial hypertension (PAH) therapies.
Posted 13 February 2012 - 01:44 AM
In this cohort, PAH therapies were associated with no clear benefits. Prospective clinical trials focusing on this group of patients are warranted. Arthritis rheumatologist. 2011 Aug;63(8):2456-64.
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
ISN Assistant Webmaster
ISN Sclero Forums Manager
ISN News Manager
ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)